OCTS USA 2022

OCTS USA 2022

Delivering Safe and Effective Adoptive Cell Therapy Products to Clinical Promise, Commercial Scale Manufacturing and Patients

Register your interest for 2022

OCTS USA 2022

Boston, USA
29-30 June, 2022

“The event was very interesting and well organised. I liked the mixture of scientific talks with updates on current developments alongside a more practical ‘logistical and regulatory’ issues one encountered in the daily life of delivering these treatments to patients in clinical trial.”

UCL

“Optimal meeting size to enable communication with all the participants. Ideal for networking ”

Celyad

Why Attend

The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements. A four-tracked agenda, featuring pioneering biopharma, academia, and solution-providers, will address all innovative MoA, manufacturing challenges, and clinical progress of CAR T, TCR T, TILs, Macrophages, and NK cells in treating haematological and solid tumors. Expect to hear from CXOs, VPs, R&D and Process Developers on the opportunities generated from recent clinical and technological data, and how they are tackling the most pressing industry challenges to get effective treatments to patients.

To facilitate connections between relevant peers and spark solution-led discussions, the summit is broken down into four streamlined tracks – Pre-clinical & Translational Research, Clinical, Manufacturing and Logistics & Market Access. You will be able to step into interactive discussions and engaging presentations on the key product development questions:

1. How to expand the durability of response by targeting antigen heterogeneity, optimized affinity, specificity and reduce cell exhaustion in the TME?
2. How can genome editing technologies lead to successful clinical applications?
3. What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies?
4. How to make the transition from proven research-scale to production-scale through a robust manufacturing platform?
5. Where to direct resources to build resilience and create a ‘vein-to-vein’ and IPSC-derived, patient-centric cell therapy supply chain?

OCTS will enable your teams to identify the rationale and progress in developing cell engineering platforms to generate a robust pipeline of potent, safe therapies. There will be a 360-view of the ongoing phase 1 / 2 trials, building out cGMP manufacturing capabilities through automation and in-process analytics, recalibrating supply chains to build resilience in a dynamic research field and ensuring novel therapies address unmet clinical need.

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell therapy academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers – CROs, CDMOs, Consultants

Last year's attendees included:

Confirmed 2022 Speakers

 

Bryan Kim

CEO / President
Verismo Therapeutics

Bryan Kim

CEO / President
Verismo Therapeutics

Bryan Kim

CEO / President
Verismo Therapeutics
 

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences
 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

 

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.
 

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine
 

Robert Hofmeister

CSO
TCR2

Robert Hofmeister

CSO
TCR2

Robert Hofmeister

CSO
TCR2
 

Eric Fedyk

VP, Program Leader, Abecma and bb2127
2seventy bio

Eric Fedyk

VP, Program Leader, Abecma and bb2127
2seventy bio

Eric Fedyk

VP, Program Leader, Abecma and bb2127
2seventy bio
 

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU
 

Kim Noonan

CSO
WindMIL

Kim Noonan

CSO
WindMIL

Kim Noonan

CSO
WindMIL
 

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma
 

Alexander Kamb

CSO
A2 Biotherapeutics

Alexander Kamb

CSO
A2 Biotherapeutics

Alexander Kamb

CSO
A2 Biotherapeutics
 

Alicia Dixon

Senior Director, Cell Therapy Operations and Patient Services
Gamida Cell

Alicia Dixon

Senior Director, Cell Therapy Operations and Patient Services
Gamida Cell

Alicia Dixon

Senior Director, Cell Therapy Operations and Patient Services
Gamida Cell
 

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka
 

Angela Scott

Co-founder and COO
TC Biopharm

Angela Scott

Co-founder and COO
TC Biopharm

Angela Scott

Co-founder and COO
TC Biopharm
 

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma
 

Anthony Colenburg Sr.

Director of Quality
Adicet Bio

Anthony Colenburg Sr.

Director of Quality
Adicet Bio

Anthony Colenburg Sr.

Director of Quality
Adicet Bio
 

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics
 

Lisa Wynja

VP, Customer Engagement
Instil Bio

Lisa Wynja

VP, Customer Engagement
Instil Bio

Lisa Wynja

VP, Customer Engagement
Instil Bio
 

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics
 

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey
 

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School
 

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm
 

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA
 

Christopher Pastorello

Director, Head of Manufacturing
Century

Christopher Pastorello

Director, Head of Manufacturing
Century

Christopher Pastorello

Director, Head of Manufacturing
Century
 

Francesco Marincola

Global Head of R&D
Kite Pharma

Francesco Marincola

Global Head of R&D
Kite Pharma

Francesco Marincola

Global Head of R&D
Kite Pharma
 

Greg Sundberg

Cell Therapy Supply Chain System Architect & Developer
Independent Consultant

Greg Sundberg

Cell Therapy Supply Chain System Architect & Developer
Independent Consultant

Greg Sundberg

Cell Therapy Supply Chain System Architect & Developer
Independent Consultant
 

Saurabh Dahiya

Assistant Professor of Medicine
University of Maryland School of Medicine

Saurabh Dahiya

Assistant Professor of Medicine
University of Maryland School of Medicine

Saurabh Dahiya

Assistant Professor of Medicine
University of Maryland School of Medicine
 

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics
 

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis
 

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics
 

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics
 

Mark Creighton-Gutteridge

VP, Head of Research
Enara Bio

Mark Creighton-Gutteridge

VP, Head of Research
Enara Bio

Mark Creighton-Gutteridge

VP, Head of Research
Enara Bio
 

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania
 

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune
 

Michael Mehler

Director, Global Site Operations
Immatics

Michael Mehler

Director, Global Site Operations
Immatics

Michael Mehler

Director, Global Site Operations
Immatics
 

Snehal Patel

Global Head, Vice President, Cell Therapy Manufacturing
Bristol Myers Squibb

Snehal Patel

Global Head, Vice President, Cell Therapy Manufacturing
Bristol Myers Squibb

Snehal Patel

Global Head, Vice President, Cell Therapy Manufacturing
Bristol Myers Squibb
 

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
 

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center
 

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences
 

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell

Register Your Interest

Register Your Interest In The Event Here

Be the first to receive the 2022 agenda! Simply fill in your details below and we will send you the agenda as soon as it’s released

Register Your Interest

Partners

Gold Event Partner

Event Partner

Media Partner

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking. Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Ryan Sanderson, Commercial Partnerships Director; [email protected].

DOWNLOAD THE SPONSORSHIP PROSPECTUS HERE.

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Wednesday, December 15, 2021 to Monday, January 31, 2022
Tier 1 - Academics
$899
Pre agenda launch price. Register now to save up to $600!
Academic & Small Biotech under $5m with active cell therapy pipeline
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Wednesday, December 15, 2021 to Monday, January 31, 2022
Tier 2 - Biotech & Pharma
$1499
Pre agenda launch price. Register now to save up $1200!
To increase your brand presence, contact Ryan Sanderson [email protected]
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Wednesday, December 15, 2021 to Friday, March 4, 2022
Tier 3 - Industry/ Service Provider
$2799
Early bird pricing until March 4, 2022. Register now to save $900!
Academic & Small Biotech under $5m with active cell therapy pipeline
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Preparing registration...

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Resources

Download Resource

Venue

Boston, MA, USA

Boston, TBD

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us